New drug combo aims to wipe out rectal cancer before surgery
NCT ID NCT05009069
Summary
This study is testing whether adding a new immunotherapy drug (tiragolumab) to an existing one (atezolizumab) can help eliminate rectal cancer more effectively after patients receive standard chemoradiation. The goal is to see if the drugs can destroy all cancer cells in the removed tumor, which may help prevent the cancer from coming back. About 58 patients with locally advanced rectal cancer will receive either the single drug or the combination before their surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
-
First Hospital of China Medical University
Shenyang, 110001, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, 310009, China
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, 510655, China
-
Zhongshan Hospital Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.